Patents Assigned to Emory University
  • Patent number: 10286113
    Abstract: The disclosure relates to compounds and compositions for bone formation, fracture treatment, bone grafting, bone fusion, cartilage maintenance and repair and methods related thereto. In certain embodiments, the disclosure relates to compositions comprising one or more compound(s) disclosed herein, such as clotrimazole, honokiol, magnolol, tacrolimus, pimecrolimus, sirolimus, everolimus, temsirolimus, spironolactone, fluticasone, fluticasone propionate, fluticasone furoate, linezolid, telmisartan, chlorambucil, retinol, isotretinoin, acitretin, etretinate, retinoic acid (tretinoin), teniposide, mitomycin C, cytarabine, decitabine, vinblastine, vincristine, vindesine, vinorelbine, valrubicin, doxorubicin, daunorubicin, epirubicin, idarubicin, mitoxantrone, pixantrone, plicamycin, pazopanib, topotecan, camptothecin, irinotecan, sunitinib, derivatives, or salt thereof, for use in bone growth processes.
    Type: Grant
    Filed: August 29, 2016
    Date of Patent: May 14, 2019
    Assignee: Emory University
    Inventors: Scott D. Boden, Sreedhara Sangadala
  • Patent number: 10286084
    Abstract: Provided herein are recombinant constructs, vectors and expression cassettes including a first promoter which is suitably a tRNA promoter operably connected to a first polynucleotide encoding a first single guide RNA and a second promoter operably connected to a second polynucleotide encoding a Cas9 polypeptide. The first single guide RNA includes a first portion complementary to a strand of a target sequence of a DNA virus and a second portion capable of interacting with the Cas9 polypeptide. Also provided are codon optimized Staphylococcus aureus derived Cas9 polynucleotides and polypeptides with nuclear localization signals and optionally an epitope tag. Also provided are constructs for production of sgRNAs including a tRNA. Methods of inhibiting viral replication, inhibiting expression of a target sequence from a virus or treating a viral infection or viral induced cancer using the compositions are also provided.
    Type: Grant
    Filed: February 18, 2015
    Date of Patent: May 14, 2019
    Assignees: Duke University, Emory University, The United States of America as Represented by the Department of Veterans Affairs
    Inventors: Bryan R. Cullen, E. Matthew Kennedy, Hal P. Bogerd, Anand Kornepati, Adam Mefferd, Raymond F. Schinazi
  • Patent number: 10278808
    Abstract: This document discusses, among other things, a system for translocating a multilayer patch. The system includes a support structure having a contact surface for bonding to the patch. The support structure has a shape configured to support the patch following separation of the patch from a surrounding tissue.
    Type: Grant
    Filed: September 29, 2014
    Date of Patent: May 7, 2019
    Assignees: Emory University, University of Minnesota
    Inventors: Timothy W. Olsen, Paul E. Loftness, Arthur G. Erdman
  • Patent number: 10273214
    Abstract: Provided are compounds, pharmaceutical compositions and methods of treating or preventing disorders associated with NMDA receptor activity, including schizophrenia, Parkinson's disease, cognitive disorders, depression, neuropathic pain, stroke, traumatic brain injury, epilepsy, and related neurologic events or neurodegeneration. Compounds of the general Formulas A-J, and pharmaceutically acceptable salts, esters, prodrugs or derivatives thereof are disclosed.
    Type: Grant
    Filed: June 2, 2014
    Date of Patent: April 30, 2019
    Assignee: Emory University
    Inventors: Stephen F. Traynelis, Dennis C. Liotta, Rose M. Santangelo, Ethel C. Garnier
  • Patent number: 10253071
    Abstract: This disclosure relates to selectin inhibitors, compositions, and methods related thereto. In certain embodiments, the disclosure relates to glycopeptides that contain one more modified amino acids conjugated to a saccharide or polysaccharide. In certain embodiments, the disclosure relates to uses of the glycopeptides as anti-inflammatory, anti-thrombotic, or anti-metastatic agents.
    Type: Grant
    Filed: May 23, 2014
    Date of Patent: April 9, 2019
    Assignees: Beth Israel Deaconess Medical Center, Inc., Emory University
    Inventors: Richard D. Cummings, Elliot L. Chaikof, Venkata R. Krishnamurthy, Mohammed Sardar
  • Patent number: 10238614
    Abstract: This disclosure relates to the use of EACA (6-aminohexanoic acid) as an antifibrinolytic for the prevention of thrombocytopenic bleeds. In certain embodiment, the disclosure relates to methods of preventing bleeding in patients with thrombocytopenia resulting from hematological malignancies by administering 6-aminohexanoic acid, salts, or prodrugs thereof prophylactically to a subject in need thereof. In certain embodiments, subjects with stable chronic thrombocytopenia previously managed with platelet transfusion represent a selected group of patients that benefit from prophylaxis.
    Type: Grant
    Filed: March 26, 2014
    Date of Patent: March 26, 2019
    Assignee: Emory University
    Inventors: Hanna Jean Khoury, Ana Antun
  • Publication number: 20190084980
    Abstract: This disclosure relates amide-sulfamide compounds disclosed herein and uses related to CXCR4 inhibition. In certain embodiments, the compounds have formula I, salts, derivatives, and prodrugs thereof wherein, A is a bridging aryl or heterocyclyl and R1 and R2 are further disclosed herein. In certain embodiments, the disclosure contemplates pharmaceutical compositions comprising compounds disclosed herein. In certain embodiments, the disclosure relates to methods of treating or preventing CXCR4 related diseases or conditions by administering an effective amount of a compound disclosed herein to a subject in need thereof.
    Type: Application
    Filed: March 14, 2017
    Publication date: March 21, 2019
    Applicant: Emory University
    Inventors: Hyunsuk Shim, Qi Shi, Renren Bai
  • Patent number: 10228378
    Abstract: The present disclosure provides methods for diagnosing and treating anxiety disorders in female subjects. Diagnosis and treatment of such anxiety disorders are based, in part, on an analysis of pituitary adenylate cyclase-activating polypeptide (PACAP) expression levels in tissue collected from female subjects.
    Type: Grant
    Filed: June 5, 2017
    Date of Patent: March 12, 2019
    Assignees: The University of Vermont and State Agricultural College, Emory University
    Inventors: Victor May, Kerry J. Ressler, Sayamwong E. Hammack, Donna Toufexis, Karen M. Braas
  • Patent number: 10227584
    Abstract: This disclosure relates to analyzing the end-to-end sequence and the relative distributions in heterogeneous mixtures of polynucleotides and methods and enabling reagents related thereto. In certain embodiments this method relates to the complete full length sequencing and quantitative profiling of mRNAs present in the transcriptomes of cells or tissues of but not limited to, higher multicellular organisms that possess interrupted genes subject to complex post-transcriptional RNA processing.
    Type: Grant
    Filed: February 17, 2014
    Date of Patent: March 12, 2019
    Assignees: Emory University, The Johns Hopkins University
    Inventors: Mark C. Emerick, William S. Agnew
  • Patent number: 10213200
    Abstract: Implementations of the disclosed technology include a forcipate surgical instrument including a channel at the working end for guiding a scalpel blade during tissue resection. In some implementations, the forceps may also include a scalpel-driven stapling mechanism for sealing the tissue simultaneously with resection via a single scalpel motion.
    Type: Grant
    Filed: December 4, 2015
    Date of Patent: February 26, 2019
    Assignee: Emory University
    Inventors: Denise Sujin Kim, Jacquelyn Borinski, Mohamad Ali Najia, Drew Padilla
  • Patent number: 10206955
    Abstract: This disclosure relates to compositions comprising ascorbic acid and bone morphogenetic protein 4 (BMP-4) for growing cells and making tissues. In certain embodiments, this disclosure relates to methods of creating cardio-mimetic tissues (CMTs) by culturing the cells in the presence of ascorbic acid and bone morphogenetic protein 4 and optionally inserting into cells a muscle specific microRNA or related nucleobase polymer and under conditions such that a cardio-mimetic tissue is formed that is capable of spontaneously contracting.
    Type: Grant
    Filed: November 5, 2015
    Date of Patent: February 19, 2019
    Assignee: Emory University
    Inventors: Young-Sup Yoon, Jaeyeaon Cho
  • Patent number: 10208107
    Abstract: Antibodies that specifically bind influenza virus hemagglutinin A (HA), and antigen binding fragments thereof are disclosed herein. In several embodiments, these antibodies are broadly neutralizing. Nucleic acids encoding these monoclonal antibodies, vectors including these nucleic acids, and host cells transformed with these vectors are also disclosed. Compositions are disclosed that include these antibodies, antigen binding fragments, nucleic acids, vectors and host cells. Method of using these antibodies, and antigen binding fragments, nucleic acids, vectors and host cells, such as for diagnosis and treatment of an influenza virus infection are also provided.
    Type: Grant
    Filed: March 29, 2016
    Date of Patent: February 19, 2019
    Assignees: Emory University, The University of Chicago
    Inventors: Rafi Ahmed, Jens Wrammert, Patrick C. Wilson
  • Patent number: 10206976
    Abstract: This disclosure relates to particles comprising recombinant proteins, pharmaceutical composition comprising the particles, and therapeutic uses related thereto. In certain embodiments, the particles are made by the process of producing recombinant proteins and conjugating the recombinant proteins to form nanoparticles with a linking reagent comprising disulfide bonds. Typically the recombinant protein has a polypeptide of viral, fungal, or bacterial origin such as secreted effector proteins AvrA and YopJ. In certain embodiments, the disclosure relates to treating or preventing autoimmune diseases, cancer, or inflammatory diseases, or conditions such as inflammatory bowel disease (IBD).
    Type: Grant
    Filed: April 5, 2018
    Date of Patent: February 19, 2019
    Assignees: Emory University, Georgia Tech Research Corporation
    Inventors: Andrew S. Neish, Julie A. Champion
  • Patent number: 10207984
    Abstract: The disclosure relates to cyclopropyl derivatives and methods of use. In some embodiments, the disclosure relates to methods of managing medical disorders with pharmaceutical compositions disclosed herein administered to subject in need thereof. In certain embodiments, the disclosure relates to methods of managing mental disorders, mood disorders, pain, and fibromyalgia and related conditions with pharmaceutical compositions disclosed herein.
    Type: Grant
    Filed: May 3, 2016
    Date of Patent: February 19, 2019
    Assignees: Emory University, Wake Forest University Health Services
    Inventors: Huw M. L. Davies, Spandan Chennamadhavuni, Thomas J. Martin, Steven R. Childers
  • Publication number: 20190038777
    Abstract: It is disclosed herein that ssAAV and scAAV vectors of the same serotype administered by injection into the cerebrospinal fluid (CSF) via the intracerebroventricular (ICV) or intrathecal (cisternal or lumbar) route exhibit different cellular tropisms in the central nervous system. Thus, a subject can be treated by injection into the CSF of ssAAV or scAAV vector encoding a therapeutic protein, such as an ssAAV9 or scAAV9 vector. The therapeutic protein can be targeted to specific cells using these vectors. In some embodiments, scAAV9 is utilized to achieve superior transduction in the hippocampus, cerebellum and cerebral cortex where both neurons, particularly Purkinje neurons, and glial cells (such as astrocytes) are transduced. In other embodiments, ssAAV9 is utilized to minimize transduction of astrocytes. In further embodiments, an immunosuppressive agent is also administered to the subject.
    Type: Application
    Filed: January 25, 2017
    Publication date: February 7, 2019
    Applicants: Emory University, REGENXBIO Inc.
    Inventors: Anthony DONSANTE, Karen KOZARSKY
  • Patent number: 10195241
    Abstract: This disclosure relates to extracts from chestnut plants and compositions comprising compounds contained therein. In certain embodiments, the extracts are derived from the leaves of a Castanea plant. In certain embodiments, the disclosure relates to methods of treating or preventing bacterial infections, acne, and other related uses.
    Type: Grant
    Filed: June 24, 2016
    Date of Patent: February 5, 2019
    Assignees: Emory University, University of Iowa Research Foundation
    Inventors: Cassandra L. Quave, James Lyles, Alexander R. Horswill
  • Publication number: 20190031758
    Abstract: PD-1 antagonists are disclosed that can be used to reduce the expression or activity of PD-1 in a subject. An immune response specific to an infectious agent or to tumor cells can be enhanced using these PD-1 antagonists in conjunction with an antigen from the infectious agent or tumor. Thus, subjects with infections, such as persistent infections can be treated using PD-1 antagonists. In addition, subjects with tumors can be treated using the PD-1 antagonists. In several examples, subjects can be treated by transplanting a therapeutically effective amount of activated T cells that recognize an antigen of interest and by administering a therapeutically effective amount of a PD-1 antagonist.
    Type: Application
    Filed: February 15, 2018
    Publication date: January 31, 2019
    Applicants: Emory University, Dana-Farber Cancer Institute, Inc., President and Fellows of Harvard College
    Inventors: Rafi Ahmed, Rama Amara, Gordon Freeman, Arlene Sharpe, Daniel Barber, E. John Wherry, Sang-Jun Ha
  • Patent number: 10188805
    Abstract: Provided are devices, systems, and methods for targeted administration of therapeutic agents to a subject. For example, provided are devices, systems, and methods for targeting the administration of peri-urethral bulking agents.
    Type: Grant
    Filed: June 9, 2015
    Date of Patent: January 29, 2019
    Assignee: Emory University
    Inventors: Niall Galloway, James Galloway
  • Patent number: 10167330
    Abstract: This disclosure relates to variable lymphocyte receptors (VLRs) modifications such as humanized sequences and polypeptides comprising such sequences that specifically bind a target molecule and uses related thereto. In certain embodiments, the disclosure relates to recombinant polypeptide VLRs disclosed herein and variants thereof. In certain embodiments, this disclosure relates to treating or preventing a disease or condition comprising administering an effective amount of a recombinant polypeptide or variant disclosed herein to a subject in need thereof.
    Type: Grant
    Filed: April 30, 2015
    Date of Patent: January 1, 2019
    Assignee: Emory University
    Inventors: Brantley R. Herrin, Max Dale Cooper, Rudolf Ehrhardt
  • Patent number: 10168341
    Abstract: A device may be configured to allow individual measuring of at least one property of at least one cell, such as measuring a contraction force of a platelet. The device may include a plurality of wells. Each well may include a hydrogel layer, the hydrogel layer including a hydrogel having a top surface that includes a pattern of cell interaction regions. The wells may differ in stiffness properties of the hydrogel and/or biochemical conditions. Each cell interaction region may include a group of at least two cell interaction sites. The spacing between each cell interaction region may be greater than a spacing between the at least two cell interaction sites of each cell interaction region. In this way, cell-cell interactions may be reduced and thereby increasing number of individual cells capable of being measured.
    Type: Grant
    Filed: March 10, 2014
    Date of Patent: January 1, 2019
    Assignees: Emory University, Children's Healthcare of Atlanta, Inc.
    Inventors: Wilbur A. Lam, David Myers, Yongzhi Qiu